Tryp Therapeutics Inc.

About Tryp Therapeutics Inc.

Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on developing transformative psychedelic medicine with known safety profiles for diseases with no effective first-line treatments. The company aims to pioneer a precision approach to psychedelics, targeting precise drug blood levels in patients, particularly through IV infusion of psilocin. Their mission is driven by patient outcomes, addressing unmet medical needs in areas like chronic pain and eating disorders.

Products & Services

IV Infusion of Psilocin (TRP-8803):A development focused on IV infusion of psilocin (active metabolite of psilocybin) to address limitations of orally administered psilocybin, providing rapid initiation and termination of the psychedelic experience with refined control over depth and duration, targeting conditions like fibromyalgia, binge eating disorder, depression, pain, and obsessive-compulsive disorders.

Synthetic Psilocybin Formulations:Proprietary formulations and novel manufacturing techniques for synthetic psilocybin and psilocin, aimed at reducing the time patients spend in the psychedelic state to improve their experience.

Specialties

Precision Psychedelic Therapy Neuropsychiatric Disorders Eating Disorders Chronic Pain Synthetic Psilocybin Development IV Infusion Techniques

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement of Unsecured Convertible Notes T: - FT: Private Placement of Unsecured Convertible Notes	A: 3215000 MR: - FA: AUD$3,215,000 FAN: 3215000	D: 2023-11-20 FD: 2023-11-20	1 investors
2	RT: Convertible Note T: - FT: Convertible Note	A: 3000000 MR: - FA: AUD$3.0 million FAN: 3000000	D: 2023-11-02 FD: 2023-11-02	1 investors
3	RT: Convertible Debt T: - FT: Convertible Debt	A: 175000 MR: - FA: AUD$175,000 FAN: 175000	D: 2023-10-11 FD: 2023-10-11	1 investors
4	RT: Convertible Debt T: - FT: Convertible Debt	A: 2400000 MR: - FA: AUD$2,400,000 FAN: 2400000	D: 2023-04-27 FD: 2023-04-27	2 investors
5	RT: Debt T: - FT: Debt	A: 2000000 MR: - FA: AUD$2,000,000 FAN: 2000000	D: 2023-04-12 FD: 2023-04-12	-

Private Placement of Unsecured Convertible Notes Latest

2023-11-20

$3.2M

1 investor (Pro only)

Convertible Note 2023-11-02

$3.0M

Convertible Debt 2023-10-11

$175K

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jason Carroll

Chief Executive Officer

LinkedIn (Pro only)

H

Hamish George

Chief Financial Officer

LinkedIn (Pro only)

J

Jim Gilligan

President & Chief Scientific Officer

LinkedIn (Pro only)

M

Michael Silverman

Chief Medical Officer

P

Peter Guzzo

VP, Drug Development

H

Herwig Janssen

Chairman

View 19 more team members with Pro

Unlock Full Team Directory

Recent News